Who Supplies Albendazole to India from IRELAND

To import finished pharmaceutical formulations containing Albendazole into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40/41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining these approvals can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory review process. For formulations under HS Code 30049099, compliance with the Drugs and Cosmetics Act and associated rules is mandatory. The Directorate General of Foreign Trade (DGFT) also requires an Importer Exporter Code (IEC) for the Indian buyer to facilitate the import process.

Imported Albendazole formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian Pharmacopoeia standards. Batch-wise testing is required, and a Certificate of Analysis (CoA) must accompany each shipment. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV, is necessary to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is conducted to verify the authenticity and quality of the imported formulations.

In April 2025, the CDSCO mandated that all imported medicines, including finished pharmaceutical formulations, must obtain import registration and licenses as per the Drugs and Cosmetics Act and associated rules. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The Public Procurement (Preference to Make in India) Order, 2017, and the Production Linked Incentive (PLI) scheme have been implemented to encourage domestic manufacturing and reduce import dependency. These policies may impact the volume of finished formulation imports, including those from Ireland.

India imports finished Albendazole formulations to meet the demand for specific dosage forms and branded products not available domestically. The domestic capacity may not fulfill the entire market requirement, leading to import dependency. The market size for Albendazole formulations in India is substantial, with a total export market of $72.5 million across 628 exporters to 150 countries.

The Basic Customs Duty (BCD) for HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable. A Social Welfare Surcharge (SWS) of 10% is levied on the BCD. The total landed duty, including all applicable taxes and surcharges, is approximately 23.536% of the Cost, Insurance, and Freight (CIF) value.

India sources finished Albendazole formulations from Ireland due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Ireland's pharmaceutical industry is known for its adherence to Good Manufacturing Practice (GMP) and regulatory compliance, making it a reliable supplier. Other suppliers include China, Germany, and the United States; however, Ireland's share in the Indian market is significant due to these advantages.

India imports finished Albendazole formulations from Ireland due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Ireland's adherence to Good Manufacturing Practice (GMP) and regulatory compliance ensures the safety and efficacy of the products. Specific formulations supplied by Ireland, such as certain tablet strengths or combination products, may not be manufactured domestically, necessitating imports.

Compared to other origins like China, Germany, and the United States, Ireland offers competitive advantages in terms of product quality, regulatory compliance, and adherence to GMP standards. While other countries may offer lower prices, Ireland's reputation for quality and reliability makes it a preferred source for importing finished Albendazole formulations into India.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers. Monitoring currency exchange rates and staying updated on regulatory changes are also crucial for effective risk management.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 40/41: Submit the application for import registration.
3. 3Drug Import License: Secure the necessary license for importing pharmaceutical products.
4. 4No Objection Certificate (NOC): Obtain NOC from the Ministry of Health and Family Welfare, if required.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm duty rates and classification.

1. Certificate of Analysis (CoA): Verify product quality and compliance.